RhumbLine Advisers
DYN icon

RhumbLine Advisers’s Dyne Therapeutics DYN Stock Holding History

RhumbLine Advisers’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.08M Sell
183,799
-3,424
-2% -$63.7K ﹤0.01% 1571
2026
Q1 		$3.39M Buy
187,223
+12,203
+7% +$210K ﹤0.01% 1598
2025
Q4 		$3.42M Buy
175,020
+7,200
+4% +$136K ﹤0.01% 1596
2025
Q3 		$2.12M Buy
167,820
+13,279
+9% +$151K ﹤0.01% 1877
2025
Q2 		$1.47M Buy
154,541
+20,914
+16% +$230K ﹤0.01% 2053
2025
Q1 		$1.4M Buy
133,627
+5,383
+4% +$77K ﹤0.01% 2007
2024
Q4 		$3.02M Buy
128,244
+3,734
+3% +$110K ﹤0.01% 1675
2024
Q3 		$4.47M Buy
124,510
+2,915
+2% +$116K ﹤0.01% 1485
2024
Q2 		$4.29M Buy
121,595
+23,266
+24% +$676K ﹤0.01% 1479
2024
Q1 		$2.79M Buy
98,329
+22,091
+29% +$500K ﹤0.01% 1735
2023
Q4 		$1.01M Buy
76,238
+5,667
+8% +$55.4K ﹤0.01% 2243
2023
Q3 		$632K Buy
70,571
+6,659
+10% +$71.7K ﹤0.01% 2471
2023
Q2 		$719K Buy
63,912
+12,732
+25% +$150K ﹤0.01% 2469
2023
Q1 		$590K Buy
51,180
+1,966
+4% +$25.5K ﹤0.01% 2372
2022
Q4 		$570K Buy
49,214
+396
+0.8% +$4.58K ﹤0.01% 2402
2022
Q3 		$620K Buy
48,818
+4,436
+10% +$50.9K ﹤0.01% 2401
2022
Q2 		$305K Buy
44,382
+6,938
+19% +$47.8K ﹤0.01% 2744
2022
Q1 		$361K Sell
37,444
-661
-2% -$5.63K ﹤0.01% 2572
2021
Q4 		$453K Sell
38,105
-285
-0.7% -$4K ﹤0.01% 2547
2021
Q3 		$623K Buy
38,390
+1,400
+4% +$24.8K ﹤0.01% 2439
2021
Q2 		$778K Buy
36,990
+25,442
+220% +$478K ﹤0.01% 2353
2021
Q1 		$179K Buy
+11,548
New +$223K ﹤0.01% 2858

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RhumbLine Advisers's DYN Position: Q2 2026 in Review

RhumbLine Advisers reduced its Dyne Therapeutics (DYN) stake by 1.8% in Q2 2026, selling an estimated $63.7K and leaving 183,799 shares worth $4.08M. The position accounts for ﹤0.01% of the portfolio, ranked #1571.

RhumbLine Advisers first reported a position in DYN in Q1 2021 and has held it in 22 quarters since. The position peaked at $4.47M in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • RhumbLine Advisers held 183,799 shares of Dyne Therapeutics worth $4.08M as of Q2 2026.
  • RhumbLine Advisers sold 3,424 Dyne Therapeutics shares in Q2 2026, an estimated $63.7K.
  • Dyne Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1571 holding.
  • RhumbLine Advisers first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • RhumbLine Advisers's Dyne Therapeutics position peaked at $4.47M in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.